Related Experiment Videos
[Prolonged curarization with suxamethonium in a four-week old infant]
D Michel1, L Simon, M M Garbay
1Département d'anesthésie-réanimation, hôpital Saint-Vincent-de-Paul, Paris, France.
Annales Francaises D'Anesthesie Et De Reanimation
|September 29, 1998
Summary
A 28-day-old infant experienced prolonged apnea after anesthesia due to a genetic condition, atypical cholinesterase. This case highlights the importance of identifying genetic factors for adverse drug reactions in infants undergoing surgery.
Area of Science:
- Anesthesiology
- Clinical Pharmacology
- Human Genetics
Background:
- Infants undergoing anesthesia for conditions like pyloric stenosis are at risk for prolonged apnea.
- Suxamethonium is a muscle relaxant commonly used in pediatric anesthesia.
- Atypical cholinesterase is a genetic variant affecting drug metabolism.
Observation:
- A 28-day-old infant developed prolonged apnea post-anesthesia.
- The infant was administered suxamethonium during surgery for pyloric stenosis.
- Genetic testing revealed the infant was homozygous for atypical cholinesterase.
Findings:
- Homozygosity for atypical cholinesterase is a rare genetic disorder.
- This genetic variant significantly prolongs the action of suxamethonium.
- The infant's prolonged apnea was directly linked to suxamethonium metabolism deficiency.
Implications:
- Early identification of atypical cholinesterase is crucial for safe anesthesia practices.
- Genetic screening may be considered for infants with a family history of adverse reactions to suxamethonium.
- Understanding genetic variations improves patient safety and anesthetic management in pediatric surgery.